Non-Alcoholic Fatty Liver Disease (NAFLD) Market Size

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Analysis

The Non-Alcoholic Fatty Liver Disease Market size is estimated at USD 21.36 billion in 2024, and is expected to reach USD 33.72 billion by 2029, growing at a CAGR of 9.56% during the forecast period (2024-2029).

Factors such as the increasing burden of non-alcoholic fatty liver disease, the rising global prevalence of diabetic and obese populations, and increasing awareness about NAFLD are expected to boost the growth of the non-alcoholic fatty liver disease (NAFLD) market during the forecast period.

As global rates of obesity, type 2 diabetes, and metabolic syndrome rise, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. This surge in NAFLD cases is driving up the demand for effective and safe drugs, fueling the market's growth. For instance, the data published by the UK Government on Liver Disease in April 2024 highlights a concerning trend: hospital admissions for liver diseases in the United Kingdom are on the upswing. Specifically, in FY2023, the admission rate climbed to 155.2 per 100,000 population, up from 150.6 the year prior. Given the increase in NAFLD-related hospital admissions, there is a heightened emphasis on early treatment, which is expected to boost the market's growth in the coming years.

Type 2 diabetes significantly heightens the risk of NAFLD progressing to fibrosis, necessitating liver transplants and even leading to mortality. For instance, data from the International Diabetes Federation, updated in 2024, forecasts that 643 million individuals worldwide will be affected by diabetes by 2030, with the figure surging to 784 million by 2045. This anticipated rise in the diabetic population amplifies their susceptibility to NAFLD, underscoring the urgent need for NAFLD screenings among diabetic patients. Consequently, this demand is poised to drive the growth of the market for novel drugs.

Globally, rising obesity rates and metabolic disorders, driven by lifestyle changes, are leading to significant health challenges and costly treatments. This scenario underscores the urgent need for effective treatment, further fueling market expansion. For instance, the World Obesity Atlas 2023 projects that the prevalence of obesity (defined as a BMI ≥30kg/m²) is expected to surge from 14% to 24% between 2020 and 2035. By 2035, nearly 2 billion individuals, spanning adults, children, and adolescents, are expected to be affected. Obesity results in excessive fat accumulation in various tissues, notably the liver, a primary factor contributing to NAFLD. Such dynamics intensify the demand for novel drugs, driving the market's growth.

Therefore, the growing burden of NAFLD, obesity, and type 2 diabetes among the population coupled with new product approvals, the studied market is expected to grow during the forecast period. However, the lack of approved drugs for non-alcoholic fatty liver disease (NAFLD) and slow advancements in the therapeutic field are likely to hinder the market's growth during the forecast period.